NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
PRGO
Perrigo Company plc
PRGO has the edge over NVO overall, supported by stronger modeled upside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
PRGO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Under pressure | |
| Weak |
PRGO's revenue is currently stable, but its profitability, cash flow and balance sheet are under pressure.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
PRGO PE Valuation
PRGO has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
PRGO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect PRGO's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over PRGO on earnings quality, reporting a profit while its opponent remains loss making.
PRGO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.53 | — |
| Q3 2026 | -$12.77 | -$12.39 |
| Q2 2026 | -$12.52 | -$11.94 |
| Q1 2026 | -$13.11 | -$11.80 |
| Q4 2025 | -$10.29 | -$9.04 |
| Q3 2025 | -$0.38 | +$0.78 |
| Q2 2025 | -$0.58 | +$0.33 |
| Q1 2025 | -$1.31 | -$1.25 |
| Q4 2024 | -$1.25 | -$1.16 |
PRGO lost $12.77 per share over the past year, a bigger loss than the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over PRGO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over PRGO on profitability, with a higher operating margin.
PRGO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $988.6M | -5.2% |
| Q2 2026 | $1B | -3.2% |
| Q1 2026 | $969.2M | -7.2% |
| Q4 2025 | $1.1B | -2.5% |
| Q3 2025 | $1B | -4.1% |
| Q2 2025 | $1.1B | -0.9% |
| Q1 2025 | $1B | -3.5% |
| Q4 2024 | $1.1B | -1.6% |
PRGO's revenue has slid since its 2020 peak: $989M last quarter, down 5.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.3% | -4.6 points |
| Q2 2026 | 2.3% | -2 points |
| Q1 2026 | -38% | -43 points |
| Q4 2025 | -116% | -126 points |
| Q3 2025 | 7% | -0.4 points |
| Q2 2025 | 4.3% | +6.8 points |
| Q1 2025 | 4.5% | +9.6 points |
| Q4 2024 | 10% | +11 points |
PRGO's operating margin was 2.3% last quarter, down 4.6 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
PRGO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $78.7M | +164% |
| Q2 2026 | $68.3M | +20% |
| Q1 2026 | -$127.4M | -$37.4M |
| Q4 2025 | $148.6M | -46% |
| Q3 2025 | $29.8M | +97% |
| Q2 2025 | $56.7M | +$75.6M |
| Q1 2025 | -$90M | -$63.5M |
| Q4 2024 | $274.9M | +51% |
PRGO still generates free cash flow, though less than at its 2021 peak: $168M over the past year.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over PRGO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
PRGO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -200K shares |
| 1 year | +0.4% | +500K shares |
| 3 years | +1.8% | +2.5M shares |
| 5 years | +4.2% | +5.6M shares |
| Available history | +1.8% | +2.4M shares |
PRGO has 139M diluted shares, about the same as a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
PRGO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 5.3x | High |
| Q2 2025 | 5.2x | High |
| Q1 2025 | 6.0x | High |
| Q4 2024 | 7.0x | High |
| Q3 2024 | 10.5x | High |
| Q2 2024 | 11.5x | High |
| Q1 2024 | 8.5x | High |
| Q4 2023 | 6.5x | High |
PRGO's net debt is about 5.3 years of its operating earnings (EBITDA), down from 10 years a year ago.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
PRGO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.8 | Neutral |
| Stochastic | 84.4 | Overbought |
PRGO's weekly RSI is 62 (neutral) and its Stochastic is 84 (overbought).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
PRGO PE vs Healthcare Sector
| Metric | PRGO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
PRGO has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
PRGO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $15.6 | 3.5% above |
| 20 week MA | $13.7 | 18% above |
| 50 week MA | $12.8 | 26% above |
| 100 week MA | $18.5 | 13% below |
| 200 week MA | $24.9 | 35% below |
PRGO has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
PRGO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.9 | $44.0 | -15% |
| 2021 | $44.0 | $39.5 | -10% |
| 2022 | $39.5 | $33.0 | -16% |
| 2023 | $33.0 | $32.2 | -2.5% |
| 2024 | $32.2 | $25.6 | -20% |
| 2025 | $25.6 | $13.8 | -46% |
| 2026 YTD | $13.8 | $16.2 | +17% |
PRGO has the edge over NVO on returns for 2026, with the stronger performance.